Search
Cardiff Oncology Inc
CRDFAdd to Watchlist
1.270USD
-0.020-1.55%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
86.83MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-02The current earnings forecast score of Cardiff Oncology Inc is 7.25, ranking 305 out of 387 in the Biotechnology & Medical Research industry. The average price target is 10.00, with a high of 19.00 and a low of 3.50.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
7.500
Target Price
+490.55%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
Cardiff Oncology Inc
CRDF
8
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Cardiff Oncology Inc's expected revenue for the next quarter?
Cardiff Oncology Inc's expected revenue is 70.71K.
What is Cardiff Oncology Inc's price target?
Analysts forecast that Cardiff Oncology Inc's price target is USD 10.00, with the highest forecast at USD 19.00 and the lowest forecast at USD 3.50.
How have Cardiff Oncology IncCRDF's recent earnings per share performed?
The market expectation was USD -0.18, while Cardiff Oncology IncCRDF's earnings per share (EPS) for the previous quarter was USD -0.11. EPS for the next quarter is expected at USD -0.16.
What is the analyst rating for Cardiff Oncology Inc?
Based on the ratings of Cardiff Oncology Inc's stock from 8 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.